To include your compound in the COVID-19 Resource Center, submit it here.

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s Nuevolution acquisition is powering its push into targeted protein degradation and the wider world of induced proximity therapies

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover multispecific therapies that trigger a broader set of biological functions.

Amgen’s rare M&A move was motivated by its Induced Proximity Platform, a unit the company launched about a year ago to develop compounds that bring two or more biological targets close enough to interact.

Setting the team’s scope to cover all forms of induced proximity, instead of just targeted protein degradation, made Amgen Inc. (NASDAQ:AMGN) among the first companies to extend the logic of PROTACs (proteolytic targeting chimeras) to other biological reactions beyond tagging proteins for degradation by the proteasome (see “Broadening the TAC Toolbox”).

The Induced Proximity Platform is the brainchild of SVP of Global Research Raymond Deshaies, who told BioCentury the strategy taps into the same “multispecific

Read the full 1516 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE